Table 5.
The primary outcome measures are based on abnormal vaginal discharge and associated symptoms of uPID.
| Abnormal Vaginal Discharge (AVD) | Pessary Group (n = 33) | Standard Group (n = 33) | p-Value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 0 | 2.78 ± 0.41 | 2.72 ± 0.51 | 0.79 | ||||||
| Day 14 | 0.36 ± 0.54 | 0.60 ± 0.86 | 0.39 | ||||||
| p value | <0.0001 | <0.0001 | |||||||
| % AVD reduction | 87.05% | 77.94% | |||||||
| Associated symptoms | Present | Relieved | Present | Relieved | |||||
| Dyspareunia | |||||||||
| Day 0 | 21 (100) | 0 | 18 (100) | 0 | |||||
| Day 14 | 3 (14.28) | 18 (85.71) | 4 (22.22) | 14 (77.77) | 0.41 | ||||
| p value | <0.0001 | <0.0001 | |||||||
| Dysuria | |||||||||
| Day 0 | 10 (100) | 0 | 10 (100) | 0 (0) | |||||
| Day 14 | 0 (0) | 10 (100) | 2 (20) | 8 (80) | 0.23 | ||||
| Pruritus vulvae | 0 | ||||||||
| Day 0 | 23 (100) | 0 | 19 (100) | 0 | |||||
| Day 14 | 0 | 23 (100) | 3 (15.78) | 16 (84.21) | 0.08 | ||||
| AVD as per severity grading | |||||||||
| AVD Grading | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | -- |
| Day 0 | 0 | 0 | 7 (21.2) | 26 (78.8) | 0 | 1 (3) | 7 (21.2) | 25 (75.8) | - |
| Day 14 | 22 (66.7) | 10 (30.3) | 1 (3) | 0 * | 19 (57.6) | 10 (30.3) | 2 (6.1) | 2 (6.1) ** | - |
| Day 30 | 28 (84.8) | 5 (15.2) | 0 | 0 * | 25 (75.8) | 5 (15.2) | 2 (6.1) | 1 (3) ** | - |
* p < 0.001 and ** p < 0.001 on day 14 and day 30 from day 0 in the pessary group and standard group respectively; unpaired ‘t’ test and paired ‘t’ test; % PR: % pain reduction at day 14 compared to day 0. Chi-square test and Fisher Exact test; AVD as per severity grading: 0—absent; 1—mild; 2—moderate and 3—profuse.